Halberd Corp (HALB)

[work-n-hard]

They've been milking Eller ever since their days at BIEI. Nothing new about that relationship.
Back then, it was CBD, but same CEO Harltless Pumping.

[HighPeaks]

That’s a pretty significant endorsement. Surprised it didn’t garner more attention. Yet.

[HighPeaks]

Any chance Halb gets into solving Monkeypox like they tried for covid.

[work-n-hard]

Damn PR. lol But really, just a bump in the road, to better buying prices.
JMO

[Louied91]

$HALB NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology

https://www.newsfilecorp.com/release/132805

Jackson Center, Pennsylvania--(Newsfile Corp. - August 4, 2022) - Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd's research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer's Disease, Parkinson's Disease, Epilepsy and suicide ideation.

The letter of endorsement from the NFL RPA comes as a result of Halberd's recent accomplishments demonstrating in-vitro elimination from cerebrospinal fluid (CSF) of multiple key inflammatory cytokines associated with head trauma and many neurodegenerative diseases. Carl Eller has spent the past two years as a consultant to Halberd, following and reviewing Halberd's development progress towards eliminating excitatory neurotransmitters (inflammatory antigens) resulting from head injuries.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist commented, "We are thrilled to have received this letter of endorsement by an organization which has such a strong interest in finding a solution to the consequences of traumatic brain injury. It is wonderful to finally see recognition of the work we have diligently performed at the universities by our very distinguished scientists. I believe that precisely eradicating the causative factors of TBI in cerebrospinal fluid, through the HALB methodology, will greatly reduce morbidity in these patients."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We would like to thank Carl Eller for this bold statement in recognition of our efforts in treating the effects of brain trauma. We look forward to support from other contact sports organizations and the military as we continue our development of our breakthrough medical technology."

[sundoctor]

Great: NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology!

[work-n-hard]

This is headed back into a good buying zone. So what's up with hitting the Ask. lol

[work-n-hard]

A few Bids starting to fill now. (Small Bids leading it down.)

[work-n-hard]

HALB headed towards Tasty again.

[Highlandmike]

Heck yeah. No prob here profiting off stupidity.
HALB

[gkare]

Six, five star reviews for Vita-Shield-Max on Amazon.

[Louied91]

$HALB Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary


https://www.newsfilecorp.com/release/131355

Jackson Center, Pennsylvania--(Newsfile Corp. - July 20, 2022) - Halberd Corporation (OTC Pink: HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled individuals are recruited to carry the subsidiary forward in its mission to develop treatments for various types of cancer. The present Halberd Corporation staff is capable of fulfilling any and all functions. With this strategy, both Halberd Corporation and Halberd Cancer Therapeutics, LTD will benefit from the initial sharing of technological accomplishments.

William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "We believe that the creation of this subsidiary is a concrete means of advancing the extracorporeal treatment technology against various forms of cancer. Halberd has already begun the development of specific cancer antibodies which will be key in near-term experimentation. Halberd anticipates that Halberd Cancer Therapeutics, LTD, could eventually be spun off as a separate company, as a dividend to Halberd stockholders. Since our technology is applicable to a wide range of diseases, we foresee the potential for the formation of additional subsidiaries aligned to specific disease applications/treatments as business opportunities and healthcare needs present themselves."

[sundoctor]

A Wholly Owned Subsidiary: Halberd Cancer Therapeutics, LTD

[gkare]

Yes, but half the country believes it. Someone tell them about HALB

[Dinesh Malta]

Lots of volume the past couple of days, Buyers are back! Someone got in BIG. It's Slappy Slappy Time. Sellers drying up means it moves up. PUMP PUMP

[Highlandmike]

Such BS.
HALB

[gkare]

Saw this on Fox today...........CBS, ABC, CNN sound the alarm on coronavirus BA.5, call for masking: ‘The worst variant is here’.

[sundoctor]

look like MMs not ready, so block the running.

[trading.jeff]

Today's volume was the heaviest since the first week of January. There were about 50% more buys that sells, today.

https://ih.advfn.com/stock-market/USOTC/halberd-pk-HALB/trades

$HALB

[Jimmy Da Neck]

Ummmmmmm, mmmmhhhhmmmm

[trading.jeff]

Already more than 8M shares traded in less than 50 minutes and the most since the volume spike of the first week of January. Will be interesting to see what today's total volume will be.

EDIT: Broke 9M a couple minutes after writing this post.

$HALB

[mplscubfan]

Phase I? II? III? FDA what say you?

[Louied91]

$HALB Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

https://www.accesswire.com/708534/halberds-antibody-effective-against-all-4-sars-cov-2-mutations-including-omicron

Boosts Effectiveness of Commercial Covid Antibodies by 45%

JACKSON CENTER, PA / ACCESSWIRE / July 14, 2022 / Halberd Corporation (OTC PINK:HALB) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd's antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%. This could lead to a treatment that is widely effective against existing and future mutations of SARS-CoV-2.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our university in-vitro lab testing showed that the HALB monoclonal antibody is able to neutralize the original Covid strain, the Covid Delta strain and the Omicron strain. We are not aware of any other monoclonal antibody which is able to neutralize the Covid Omicron strain with this level of efficiency. Our proprietary monoclonal antibody has the potential to substantially increase the efficacy of the commercially available intravenous monoclonal antibody infusion treatment for Covid. Given the consistency at which our antibody has worked across current multiple mutations, Halberd's monoclonal antibody is more likely to be effective in treating current and/or future variants than commercially available treatments. Since we know that Covid-19 is quite susceptible to mutating, Covid is almost impossible to eradicate unless the treatment is effective against future variants."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We are currently in discussions with our patent attorney to determine the breadth of intellectual property available to Halberd. We expect the outstanding results achieved in our laboratory testing will spawn several patents and garner enhanced interest beyond our recent preliminary industry discussions."

[gkare]

UP WE GO!

[JJZander]

Nice news

[sundoctor]

HALB Great News for Omicron!

[sundoctor]

history repeat? After a ceo letter in July 2021, HALB run.

[Louied91]

$HALB Halberd Corporation Update, CEO Letter and 2022 Expectations


https://www.newsfilecorp.com/release/130604

Q2 Accomplishments and a Look to the Future

Jackson Center, Pennsylvania--(Newsfile Corp. - July 12, 2022) - Halberd Corporation (OTC Pink: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows:

2Q ACHIEVEMENTS

Added an animal testing expert (DVM/PhD) to our list of scientific consultants to plan and execute extensive animal testing of Halberd's patented extracorporeal process for the removal of targeted disease antigens.

Our first scientific article on our revolutionary R&D achievements has been drafted and is undergoing reviews internally by our patent attorney to ensure any technology disclosed in the article is appropriately and accurately covered by patent applications before being submitted for publication to peer-reviewed journals.

Halberd engaged the services of former pharmaceutical personnel to assist in tailoring our presentation material and pitch deck for future contacts with potential investors and Big Pharma.

Work is continuing with the NFL retired Players Association to seek their endorsement of Halberd's R&D to effectively treat Traumatic Brain Injury (TBI)/Chronic Traumatic Encephalopathy (CTE) and the associated neurodegenerative diseases emanating from the types of hits players experience in games.

Letter sent to NCAA contact seeking help in securing NCAA endorsement for Halberd's R&D to effectively treat TBI & CTE which can result from participation in contact sports at the college level.

Dr. William G. Sturrus delivered a TEDx Talk on the work that he has participated in to demonstrate Halberd's extracorporeal technology in eliminating select target antigens from cerebrospinal fluid (CSF) through exposure to laser emissive energy.

Initiated testing of Halberd's patent-pending chemical bonding process for extracorporeal elimination of select disease antigens from bodily fluids, which enhances the flexibility of application to patients and would eliminate the need for laser or radio frequency irradiation.

Halberd initiated studies to create several separate divisions that will enable adequate focus on related-yet-different technical entities: 1) Cancer and 2) Anti-Addiction are two divisions under consideration.

Completed initial evaluation of NFT's. Management has agreed to postpone decision until a later date pending further progress on Halberd's on-going R&D, its market valuation and the stabilization of the cryptocurrency and token markets.

Halberd has consolidated responsibility for managing market reactions, and media relations.

A contract has been signed with New-To-The-Street for a series of appearances, to begin after the successful completion of animal testing at Mississippi State University (MSU).

Halberd engaged mdi Consultants, Inc., a consulting firm that specializes in assisting companies to navigate the FDA's complex requirements to obtain authorization to market medical devices/procedures. The purpose is to enable us to better navigate the FDA requirements as we initiate animal testing.

Halberd will work with mdi Consultants in potentially obtaining FDA Emergency Use Authorization of Halberd's technology for select conditions and afflictions.

Met with a Department of Defense (DoD) official regarding potential contract. Further meetings with a wider audience anticipated.

Halberd submitted audited financials to the SEC in its application for uplisting to the OTCQB. As is typical with the process, the SEC responded with a request for additional information, which Halberd is addressing.

THE LOOK AHEAD

Halberd will continue its journey towards developing successful treatments for neurodegenerative diseases utilizing its patented extracorporeal treatment process through laser irradiation of treated bodily fluids, or removal through its patent-pending chemical bonding processes.

The next step on this journey entails conducting animal testing using Halberd's extracorporeal eradication processes.

Halberd will apply its extracorporeal treatment to whole blood, blood plasma and blood serum to ensure there is no collateral damage to necessary elements in these fluids and only the target disease antigens are eliminated.

Elimination of target disease antigens from blood opens the door to a wide range of disease treatment possibilities for bacterial and viral infections.

Halberd will continue its organizational changes to structure dedicated subsidiaries which can utilize Halberd's underlying technologies to develop treatments for specific diseases/conditions, with the intent of eventually spinning off these subsidiaries into separate publicly traded companies. Halberd shareholders will become shareholders in any spin-off company.

SUMMARY

Halberd achieved significant progress this past quarter and as we accomplish each milestone, we see additional opportunities for creating value for Halberd shareholders as we fine-tune the applications. Our testing to date continues to demonstrate the superiority of our technology in eliminating disease antigens without the potentially dangerous side-effects associated with many injected or ingested drugs.

We believe in our mission to create and develop safe and effective treatments against many previously perceived incurable diseases and continue to make progress towards achieving that goal.

We appreciate the efforts of our expanding team of research scientists, and the support of our stockholders. We will continue to maintain transparency and regular communication with interested parties.

Sincerely,

William A. Hartman
Chairman, President & CEO

[work-n-hard]

Can't say, but they have been known to "skip" entire tickers. (BIEI)

[gkare]

I was expecting PR updates regularly. I hope they didn't skip town.

[work-n-hard]

Somebody is getting a decent flip out of yesterday.

[work-n-hard]

1M Buys / 2.8M Sells / 360K ? / Closed Down 11.46% @ .0139
LOD was .0092

[sundoctor]

no news before holiday is good news?

[work-n-hard]

Great Minds.... :)

[trading.jeff]

$HALB pps is right where it was last July and chart is showing a triple bottom. Other than these two things, I can't say much.

BTW, we should stop running into each other everywhere. I think this makes at least three stocks we're in and/or posting about together. haha

[work-n-hard]

Now THAT is 1 ugly chart: https://www.barchart.com/stocks/quotes/HALB/technical-chart?plot=BAR&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=0&sym=HALB&grid=1&height=500&studyheight=100

[Aero-man]

Halberd must be getting close to the target – just look at the BS-flack thrown up by Just-keep-dying, Jerk-n-hard and Invest-in-stupidity. Looks like all the same whack-job.

[Invest-in-America]

HALB: But, wait-a-minute!!! BREAKING NEWS!!! HALB's MICE Study results are in!!! (See below!!!)

(Global-Scams-Newswire, 6-26-22):
"HALB Company's Ground-Breaking, Senile Dementia, MICE Study Demonstrates Conclusively That ALL Mice Treated With HALB's (Patented) Extra-Corporeal-Human-Body-Fluids-FIXING-Process Enabled All Former (Severely-Afflicted) Alzheimer's MICE To Run Their Respective Test MAIZES In Only 5-SECONDS-FLAT --- Vs. The Laborious 20-MINUTES (On Average) For All Other Standard-Of-Care, Placebo, & Otherwise Control Groups Of MICE Comprising HALB's Milestone, Watershed, & Revolutionary Animal Study!"

////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////


////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////[/b

[Invest-in-America]

HALB: The legendary P. T. BARNUM himself would be PROUD of the over-the-top, phantasma-gorical, surrealistic, & otherwise scientific/scholarly-sounding VERBIAGE of this OTC-ALL-TIME-AWARD-WINNING-SCAM "company"!!!!

///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
"Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus - - -
The treatment methodology entails using a specifically created antibody conjugated with a radio frequency reactive (metallic) moiety which binds with the target antigen (SARS-COV-2 or any other identified virus or disease antigen) in an extracorporeal mixing chamber. The infected patient's blood would pass through the mixing chamber where the antibody-metallic moiety binds with target antigens in the blood. The conjugated antibody-antigen-metallic moiety compound would then be subjected to specifically tuned radio frequency (RF) signals designed to destroy the target antigen. Any residual material would be filtered from the blood before being returned to the patient. This conjugation-irradiation-filtration process would be conducted in real-time on a continuous flow basis, much like kidney dialysis."

(Quoted in relevant parts --- actually, in IR-relevant parts!!!)
RE: https://finance.yahoo.com/news/halberd-corporation-pursues-extracorporeal-radio-130000599.html
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

[Invest-in-America]

HALB: The uncanny similarities between HABL's "Drive-Thru-Extra-Corporeal-Human-Body-Fluids-Exchange-Shops" --- and VALVOLINE's "Drive-Thru-Oil-Change" franchises --- are shocking!!!! Indeed, it looks like a classic (looming)TRADE MARKS, PATENTS, & COPYRIGHTS misappropriation Civil Actiion vs. HALB Company, to me!!!!
https://finance.yahoo.com/news/halberd-corporation-pursues-extracorporeal-radio-130000599.html
https://www.groupon.com/deals/valvoline-instant-oil-change-62
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

[Invest-in-America]

HALB: "Take a look at one year chart", you say??? Well, yes indeed, HALB has CRASHED to circa just ONE-FIFTH of its price back a year ago. What did you EXPECT the PRICE of a Classic, fake-news, scamming, & (Patently) reprobate company to demonstrate over a ONE-YEAR length of time???


"Hey, let's get OFF the subject of HALB's patently ABSURD 'extra-corporeal' bullshit, Dude --- we don't want to DIE LAUGHING at an early age!!! But then --- what the hell --- I'm takin' my Chevy truck's blown-out ENGINE over to HALB's proving grounds to see if they can FIX IT vis-a-vis simply TRANSFUSING its engine OIL!!!"

[sundoctor]

are you brother/sister of Just-Keep-Trying and work-n-hard? take a look at one year chart.

[Invest-in-America]

HALB Update!!! Company Wins Prestigious, "OTC'S-GREATEST-SCAM-OF-CALENDAR-YEAR-2022-TROPHY-AWARD!!" (See film, below!!)


"HALB Company's VP --- 'PetriDish' (Wife of CEO) --- Proudly Flaunts Company's Prestigious 'OTC-SCAM-OF-THE-YEAR' Trophy For 2022!" (Access.SCAMS.NewsWire.com).

[Invest-in-America]

What a scam this is! HOW does anyone believe ANY of the baloney that HALB puts out???????????????

[sundoctor]

look like mms are testing market.

[Louied91]

$HALB Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

https://www.accesswire.com/705872/halberd-creates-subsidiary-to-apply-its-patented-technology-to-treat-cancer

JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd's technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments.

The subgroup will be guided by Halberd's existing technical team members, but will add the necessary expertise to carry the program forward without diluting its current efforts towards alleviating neurodegenerative diseases, such as Alzheimer's Disease (AD), PTSD/Chronic Traumatic Encephalopathy (CTE), Traumatic Brain Injury (TBI), Epilepsy, depression, suicide ideation, etc. Halberd's technology has been shown in the laboratory to be effective against viral and bacterial infections as well.

Halberd anticipates that the new cancer subgroup could eventually be spun off as a separate company, as a dividend to Halberd stockholders. With this strategy, Halberd Corporation will not merely benefit from the sharing of technological accomplishments, but will also enjoy royalties from its application to cancer treatments.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our earlier experience with the development of cancer antibodies, coupled with the recent successes we demonstrated eliminating targeted inflammatory cytokines, proteins, etc., leads me to believe that this may be the first step towards developing a cure for a wide variety of cancers. Our plan is to develop three major cancer antibodies (PD-1, BTLA, and CTLA-4) that could be used to effectively eradicate many cancers while employing Halberd's patented extra-corporeal eradication methodology. We plan to test these antibodies for efficacy in the laboratory, near term.

Dr. Felder continued, "Halberd's new cancer subgroup is already proceeding with the development of a PD-1 antibody which may be combined with a metallic moiety for elimination through laser irradiation. We believe that we may have the other antibodies available in the next few weeks. The goal is to develop a more effective cancer treatment without the negative side-effects associated with most current treatments. Animal tests of our proprietary antibodies will follow successful in-vitro laboratory tests. Significantly, since it is the same basic technology, the findings with regard to these antigens will only enhance the application with regard to viruses, bacterial infections and other applications pursued by Halberd's research."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We believe that the creation of a separate Cancer Treatment Division of the Halberd Corporation is a viable and prudent step in creating not only a more effective and less debilitating treatment for cancer, but for creating tremendous shareholder value. We remain dedicated to continuing our current focus to eradicate neurodegenerative diseases via lasers, chemical bonding, and radio frequency methods, now being further advanced via animal testing. We will not dilute our priority neurodegenerative disease focus while getting the cancer subgroup up and running with additional resources."

To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

[sundoctor]

good or bad news: cancer?

[sundoctor]

get it. bigs got huge from 19 vaccine conditional approval.

[Just-Keep-Trying]

HALB: If THAT "Veterinarian" school has ANYTHING at all to do with this (Patently) SCAMMING Company, well, then they themselves should be ARRESTED!!
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
HALB (AssociatedPress, 6-17-22): "Halberd Corp. (HALB, OTCMKTS) today demonstrated that their Patented "Extracorporeal Process" can quickly & easily REMOVE all disease-causing substances from HUMAN URINE --- just like from Human BLOOD & SPINAL FLUIDS. Then, when said URINE is RETURNED to the patients' BLADDERS, they remain completely FREE of all BLADDER and/or URINARY TRACT infections, cancers, & otherwise DISEASES for the remainder of their natural lives." (Quoted in relevant part.)


"Hey, last time I saw a SCAM COMPANY like this one, it was in a SIDESHOW at a local Ringling Brothers, Barnum & Bailey, CIRCUS! Right next to the Three-Headed Woman, the Dog-Faced Boy, and the Wild Man From BORNEO!!"

[Aero-man]

Halberd and other small bio-tech firms must go through rigorous FDA Phase I safety studies on animals - mean-while Pfizer and Moderna have been doing their killer-clot-shot studies on live human subjects, while collecting many $Billions from the tax payer. Looks to be FDA and Big-Pharma crimes against humanity.